Stuart Naylor Buys Shares of MeiraGTx Holdings
Stuart Naylor, Chief Scientist at MeiraGTx, acquired 70,000 shares.
Key Points
- Stuart Naylor, Chief Scientist at MeiraGTx Holdings, purchased 70,000 shares on June 25, 2026.
- Shares of NasdaqGS:MGTX traded at $12.54 on Tuesday, with a market cap of $1.12 billion.
- Analysts maintain a strong buy consensus with a mean target price of $28.25 for MeiraGTx.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 25, 2026, Stuart Naylor, the Chief Scientist of Ophthalmology at MeiraGTx Holdings plc, purchased 70,000 shares of the company's stock. The transaction was not part of a pre-planned trading program, and the shares were acquired at no cost, according to the filing. This move adds to the insider activity at the company as other executives also made significant purchases on the same day.
Insider Buying and Selling at MeiraGTx Holdings plc
In addition to Stuart Naylor, several other insiders at MeiraGTx Holdings made notable purchases. President and CEO Alexandria Forbes acquired 980,000 shares, while General Counsel Robert Wollin and Chief Medical Officer Robert Zeldin each bought 100,000 shares. CFO and COO Richard Giroux also bought 980,000 shares. These transactions suggest a strong internal confidence in the company's prospects.
MeiraGTx Holdings plc Stock Down 9.3%
Shares of MeiraGTx Holdings, traded under the ticker MGTX on the NasdaqGS, were priced at $12.54 on Tuesday. The company has a market capitalization of approximately $1.12 billion. MeiraGTx's forward P/E ratio is not meaningful as it is currently not profitable. The stock's 52-week range is between $6.31 and $12.28, with a 50-day moving average of $9.86 and a 200-day moving average of $8.52. The company's current and quick ratios indicate limited short-term liquidity.
$MGTX stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts continue to show strong support for MeiraGTx Holdings. On May 15, 2026, RBC Capital maintained its 'buy' rating with a price target of $25. Piper Sandler also maintained a 'buy' rating with a $30 target on April 22. The consensus among analysts is a 'strong buy', with a mean target price of $28.25 based on eight analyst opinions.
About MeiraGTx Holdings
MeiraGTx Holdings plc is a biotechnology company based in New York, New York. It focuses on developing genetic medicines for treating serious diseases, particularly in ocular and neurodegenerative fields. The company is advancing various therapies, including treatments for inherited retinal diseases and Parkinson's disease. Founded in 2015, MeiraGTx collaborates with major partners like Johnson & Johnson to enhance its research and development efforts.
Bottom Line
Stuart Naylor's purchase of MeiraGTx Holdings shares is part of a broader insider buying trend at the company, indicating confidence in its future. Investors will be watching how these insider moves align with the company's performance and upcoming earnings report on August 13, 2026. As always, it's important to remember that insider transactions are disclosed after the fact and don't necessarily predict future stock performance.
Get MeiraGTx Holdings plc alerts
New 13F filings, insider trades, and analyst moves on $MGTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.